*NEW LINK* 14th Annual North Carolina Research Triangle Pulmonary Hypertension Symposium

Associate Professor of Medicine
Director, Pulmonary Hypertension Program
Division of Pulmonary and Critical Care Medicine
University of North Carolina at Chapel Hill

TARGET AUDIENCE: This program is designed to meet the continuing education (CE) needs of pulmonologists, cardiologists, nurses, pharmacists, and other allied healthcare professionals involved in the treatment of pulmonary hypertension.

LEARNING OBJECTIVES: At the conclusion of this activity, participants should be able to:

Describe the classification of Pulmonary Hypertension, according to the World Symposium classifications and including updates from the 6th World Symposium, as well as the treatment options with respect to PAH-specific therapies.
Recognize and distinguish similar disease processes that may or may not respond to Pulmonary Arterial Hypertension specific therapy. These in part include PH associated with congenital heart disease, parenchymal lung disease, left heart and lung disease as well as liver disease. Cases will afford examples to think about the intricacies of these issues in patient care.
Congenital Heart disease-associated PAH is part of the WHO Group 1 classification. Recognize treatment and care specific to this population.
WHO Group 3 Pulmonary Hypertension related to lung disease is undergoing a resurgence of interest. Explain who is a candidate for therapy and when to initiate.
Up to 70% of people with pulmonary arterial hypertension are women. Describe the differences in gender in terms of risk, and response to therapy.
While we are fortunate to have available multiple medications over the last 10 to 20 years, the treatment options have become more complex. Discuss combination therapy and changing therapies in response to Insurance pressures, lack of efficacy, and side effects.
Pulmonary arterial hypertension is a progressive disease and it is imperative to continually assess disease progression and risk stratification. Examine Risk Calculators and Profiles to help initiate ideal upfront therapy and further adjust medications throughout the care period.
Pulmonary arterial hypertension is treatable but not curable at this time. New medications and pathways are actively being investigated for use in pulmonary arterial hypertension. Recognize these newer medications/pathways and applications of these.
Lung Transplantation/Heart-Lung is used when PH meds fail. Explain which patients are candidates and the time frame to consider this option. Describe pre- and peri-transplant processes.

Please email Christy Darnell with any questions.

JOINT ACCREDITATION STATEMENT:

This activity has been planned and implemented by the Duke University Health System Department of Clinical Education & Professional Development for the advancement of patient care. In support of improving patient care, the Duke University Health System Department of Clinical Education & Professional Development is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the health care team.

Category 1: Duke University Health System Department of Clinical Education and Professional Development designates this activity for a maximum of 6 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Nurse CE: Duke University Health System Department of Clinical Education and Professional Development designates this activity for up to 6 credit hours for nurses. Nurses should claim only credit commensurate with the extent of their participation in this activity.

Pharmacists: Duke University Health System Department of Clinical Education and Professional Development designates this activity for a maximum of 6 ACPE credit hours. Universal Activity Number: JA0000655-0000-22-150-H04-P

REGISTRATION FEES FOR LIVE EVENT*

$195:	Physicians, Industry Representatives
$60:	Non-Physician Clinicians, Allied Health, Residents, and Fellows

*Registration fees include all symposium materials, breakfast, lunch and breaks.

REGISTRATION FOR ENDURING CONTENT
Registration for the enduring content is complimentary but required.